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The WHO Strategic Advisory Group of Experts is reviewing the technical evidence to inform 
policy on optimal use of infant pneumococcal conjugate vaccines (PCV)(1). Since 2010, 
multivalent vaccines (PCV-10, PCV-13) have been successfully introduced with the support 
of Gavi the Vaccine Alliance into infant immunisation programmes across the developing 
world(2).  One recommended schedule consists of three doses under the age of 6 months 
(3+0), with the aim of providing maximum protection to infants, the age group at highest 
risk of pneumococcal disease(3). An alternative schedule consists of two vaccine doses 
under the age of six months with a booster at 9-15 months (2+1). This schedule may have 
more impact on reducing carriage and transmission of vaccine serotypes to unvaccinated 
individuals, leading to indirect or herd protection. The question around the most cost 
effective policy to achieve both direct and indirect protection has particular importance for 
the meningitis belt of sub-Saharan Africa.    
 
The launch of mass campaigns with a serogroup A conjugate vaccine (MenAfriVacR) across  
the meningitis belt in 2010 saw a dramatic fall in the incidence of meningitis due to 
serogroup A, while meningitis due to other meningococcal serogroups and Streptococcus 
pneumoniae have become more prominent(4).  Recent publications from the meningitis 
belt emphasise the continuing burden of pneumococcal meningitis among older children 
and adults in this region. In Ghana, a large outbreak occurred in 2016 with close to 900 
suspected cases and 104 cases confirmed as due to S.pneumoniae, mainly serotype 1, with 
a median age of 20 years, in part of the country adjoining the meningitis belt(5). In Burkina 
Faso from 2011-13, 1,528 (53%) of 2,858 cases of laboratory confirmed bacterial meningitis 
were due to S.pneumoniae, also mainly serotype 1(6). The proportion of cases aged over 5 
years was 95% in Ghana and 69% in Burkina Faso. PCV programmes that started in 2013 in 
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Ghana likely protected young children in the 2016 outbreak, whereas the Burkina Faso 
data were taken from the years preceding PCV vaccination.    
 
Bacterial meningitis due to S. pneumoniae has a remarkably high  case fatality ratios in Sub-
Saharan Africa(7) and causes much disability in survivors(8). A systematic review of 
paediatric meningitis in children in Africa found among cases of confirmed pneumococcal 
meningitis that the median in-hospital case fatality ratio was 35% and that 25% of survivors 
had in-hospital sequelae, these figures being 9x and 4x higher respectively than those for 
meningococcal meningitis(8). Incidence of pneumococcal meningitis is particularly high in 
the meningitis belt, with a similar seasonality to meningococcal meningitis, consistent with 
similar predisposing environmental factors(7, 9). Reducing the burden of pneumococcal 
meningitis in these countries should be given high public health priority.  
 
For outbreak control, pneumococcal vaccines could potentially be given to children and 
adults in reactive mass campaigns, a similar strategy to that using meningococcal vaccines 
for controlling outbreaks of meningococcal meningitis(10). However, reactive vaccination 
for meningococcal meningitis is resource intensive and relatively ineffective unless 
undertaken promptly (11, 12) and  effectiveness of such a policy in controlling outbreaks of 
pneumococcal meningitis is not known(13). Preventive vaccination offers more hope. Even 
though serotype 1 is rarely found in carriage isolates, evidence of indirect protection 
against serotype 1 was found in South Africa after introduction of a 2+1 PCV-13 infant 
vaccination schedule (14).  
 
How best can we achieve indirect protection of older age groups at high risk of 
pneumococcal meningitis in the meningitis belt? Inclusion of  a booster dose may be more 
important for some serotypes, including serotype 1(15), and extended vaccination among 
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children up to the age of 5 years, in whom carriage prevalence is highest in sub-Saharan 
Africa(16), may increase effectiveness(2, 17). A 3+0 schedule supplemented by a catch up 
campaign to the age of 5 years in Kenya reduced carriage of vaccine serotypes in 
vaccinated and unvaccinated age groups(18). In contrast, a study from the Gambia showed 
no evidence as yet of a reduction in serotype 1 disease in persons aged >5 years after 
introducing a 3+0 PCV-13 schedule without catch up in 2011(19), and the pneumococcal 
meningitis outbreak this year in Ghana occurred despite the prior introduction of a 3+0 
schedule with high coverage in the two previous years. Most countries of the meningitis 
belt have introduced a 3+0 schedule. Switching to a 2+1 schedule with a single dose catch 
up in children up to 5 years of age could extend individual protection, lead to a higher level 
of indirect protection and lower the risk of outbreaks  from this devastating disease.   
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